Sales of pulmonary fibrosis biomarkers are expected to accelerate at a CAGR of 4.4% from 2024 to 2034. The pulmonary fibrosis biomarker market is projected to increase from US$ 4,353.0 million in 2024 to US$ 6,538.4 million by 2034. The market was valued at US$ 4,149.0 million in 2023.
Increased developments in pulmonary fibrosis biomarkers, making it easier to find and validate new biomarkers and integrate them into clinical practice, contribute to the market expansion of pulmonary fibrosis biomarkers. The market is witnessing growth due to the application of bioinformatics tools and the development of high-throughput screening techniques.
| Attributes | Details |
|---|---|
| Pulmonary Fibrosis Biomarker Market Size (2024) | US$ 4,353.0 million |
| Expected Market Size (2034) | US$ 6,538.4 million |
| CAGR (2024 to 2034) | 4.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Attributes | Details |
|---|---|
| Pulmonary Fibrosis Biomarker Market Value (2018) | US$ 3,330.6 million |
| Estimated Market Value for 2023 | US$ 4,149.0 million |
| CAGR from 2019 to 2023 | 4.5% |
Principal Consultant
The progressive pulmonary fibrosis (PPF) treatment market and the EPO biomarker market have both been studied in comparison to the pulmonary fibrosis biomarker market. The data depicted in the tables below highlights the projected CAGRs, key trends, and opportunities in these markets.
Pulmonary Fibrosis Biomarker Market:
| Attributes | Pulmonary Fibrosis Biomarker Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 4.4% |
| Growth Factor | The increasing focus on precision medicine propels the demand for novel biomarker assays in diagnosing pulmonary fibrosis. |
| Market Trend | Treatment response and the advancements of pulmonary fibrosis are monitored with minimally invasive methods because of liquid biopsy-based biomarkers. |
| Market Restraint | The lack of consistent validation hinders the wide adoption of pulmonary fibrosis biomarkers. |
Progressive Pulmonary Fibrosis (PPF) Treatment Market:
| Attributes | Progressive Pulmonary Fibrosis (PPF) Treatment Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 7.5% |
| Growth Factor | The field of PPF treatment is changing as a result of new anti-fibrotic medications. |
| Market Trend | Personalized PPF therapy is becoming more popular with the use of precision medical techniques. |
| Market Restraint | Patients find it difficult to afford the high cost of new PPF therapies. |
EPO Biomarkers Market:
| Attributes | EPO Biomarkers Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 5.3% |
| Growth Factor | A growing emphasis on the management of anemia in chronic illnesses fuels the demand for EPO biomarkers. |
| Market Trend | EPO biomarker testing to detect doping is becoming more prevalent in sports medicine. |
| Market Restraint | The absence of agreement on standardized EPO biomarker assays inhibits the wide adoption of the test. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Top Type | Segment Share (2024) |
|---|---|
| Imaging Tests | 50.8% |
| Top Indication | Segment Share (2024) |
|---|---|
| Idiopathic pulmonary fibrosis (IPF) | 42.6% |
| Top End User | Segment Share (2024) |
|---|---|
| Hospitals | 33.4% |
This section examines the pulmonary fibrosis biomarker markets in several significant economies, such as the United States, Spain, the United Kingdom, India, and China. It also explores different factors that influence pulmonary fibrosis biomarker demand, adoption, and sales across these countries.
| Country | CAGR (2024 to 2034) |
|---|---|
| China | 11.4% |
| India | 6.9% |
| Spain | 8.2% |
| United States | 3.5% |
| Germany | 5.5% |
Key pulmonary fibrosis biomarker manufacturers significantly shape the sector's competitive landscape. Known for its dedication to innovation, Biogen welcomes Veracyte, which is one of the significant pulmonary fibrosis biomarker providers, emphasizing cutting-edge diagnostic solutions.
Galapagos NV offers its advantages to the market, while Genentech, a Roche company, adds its pharmaceutical knowledge. Biocartis and Myriad Genetics are essential in pulmonary fibrosis biomarkers since they offer specific solutions.
These key pulmonary fibrosis biomarker vendors work together to enhance research and development, which supports the market's general expansion and development for pulmonary fibrosis biomarkers. Their combined efforts highlight the pulmonary fibrosis biomarker industry's dynamic nature as it continues to tackle the difficulties related to pulmonary fibrosis.
Latest Advancements
The pulmonary fibrosis biomarker was valued at US$ 4,149.0 million in 2023.
The demand for pulmonary fibrosis biomarkers is set to reach a valuation of US$ 6,538.4 million by the end of 2034.
The market is anticipated to expand at a 4.4% CAGR through 2034.
The imaging tests segment is expected to acquire a market share of 44.9% in 2024.
Sales of pulmonary fibrosis biomarkers are estimated to be valued at US$ 4,353.0 million in 2024.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Area Development/Innovation Trends 4. Value Added Insights 4.1. Product Assessment 4.1.1. Product Adoption Analysis 4.1.2. Product USP's/Features Analysis 4.1.3. Recent Product Launches and Innovations 4.2. Regulatory Guidelines 4.2.1. Legal Requirements and Frameworks in the USA 4.2.2. Legal Requirements and Frameworks in Europe 4.2.3. Legal Requirements and Frameworks in Japan 4.2.4. Legal Requirements and Frameworks in China 4.2.5. Legal Requirements and Frameworks in India 4.2.6. Legal Requirements and Frameworks in Australia 4.3. Disease Epidemiology, By Key Countries 4.3.1. Prevalence of Population, By Country 4.3.2. Gender and Age-Specific Cases 4.3.3. Severity-Specific Cases 4.3.4. Diagnosed Prevalence Cases 4.4. Pipeline Assessment 4.4.1. Comprehensive Assessment by End Users 4.4.2. By Disease Indication 4.4.3. Emerging Novel trends 4.4.4. Late-stage Pipeline Assessment 4.5. Porter’s Analysis 4.6. Regional PESTEL Analysis 4.7. Value Chain Analysis 4.8. Unmet Needs Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure Outlook 5.1.2. Global Life Expectancy Outlook 5.1.3. R & D Funding By Region 5.1.4. R & D Funding By Country 5.1.5. R & D Spending, By Pharma Players 5.1.6. Top 25 Companies by R & D Spend in 2023 5.1.7. Parent Market Outlook 5.2. Forecast Factors - Relevance and Impact 5.2.1. Regulatory Initiatives and Incentives 5.2.2. Technological Advancements in Trial Design 5.2.3. Patient-Centric Approaches and Advocacy 5.2.4. Global Collaborations and Partnerships 5.2.5. Increased Focus on Rare Diseases 5.2.6. Inclusive Trial Designs for Diverse Populations 5.2.7. Ethical Considerations and Informed Consent 5.2.8. Advancements in Pediatric Precision Medicine 5.2.9. Integration of Real-World Evidence (RWE) 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2023 and Forecast, 2024 to 2034 6.1. Historical Market Value (US$ Million) Analysis, 2018 to 2024 6.2. Current and Future Market Value (US$ Million) Projections, 2024 to 2034 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Test Type 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) By Test Type, 2018 to 2023 7.3. Current and Future Market Size (US$ Million) and Forecast ty Test Type, 2024 to 2034 7.3.1. Blood Tests: 7.3.1.1. C-Reactive Protein Testing Kits 7.3.1.2. Antibody Testing Kits 7.3.1.2.1. Antinuclear Antibodies (ANA) Test 7.3.1.2.2. Anti-CCP antibody testing 7.3.1.3. ESR Tests and CBC 7.3.2. Imaging Tests 7.3.2.1. X-rays Scans 7.3.2.2. HRCT Scans 7.3.3. Lung Biopsy 7.4. Market Attractiveness Analysis by Region 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis by Indication, 2018 to 2023 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Indication, 2024 to 2034 8.3.1. Idiopathic pulmonary fibrosis (IPF) 8.3.2. Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD) 8.3.3. Drug-induced pulmonary fibrosis 8.3.4. COVID-19-related pulmonary fibrosis 8.3.5. Pneumoconiosis 8.3.6. Sarcoidosis 8.3.7. Others 8.4. Market Attractiveness Analysis By Test 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) By End User, 2018 to 2023 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2024 to 2034 9.3.1. Hospitals 9.3.2. Specialty Clinics 9.3.3. Diagnostic Laboratories 9.3.4. Diagnostic Imaging Centers 9.4. Market Attractiveness Analysis by End User 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2018 to 2023 10.3. Current and Future Market Size (US$ Million) and Forecast by Region, 2024 to 2034 10.3.1. North America 10.3.2. Latin America 10.3.3. East Asia 10.3.4. South Asia and Pacific 10.3.5. Western Europe 10.3.6. Eastern Europe 10.3.7. Middle East and Africa 10.4. Market Attractiveness Analysis by Region 11. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 11.3.1. By Country 11.3.1.1. USA 11.3.1.2. Canada 11.3.1.3. Mexico 11.3.2. By Test Type 11.3.3. By Indication 11.3.4. By End User 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Test Type 11.4.3. By Indication 11.4.4. By End User 11.5. Market Trends 11.6. Drivers and Restraints - Impact Analysis 11.7. Country Level Analysis and Forecast 11.7.1. USA Market Analysis 11.7.1.1. Introduction 11.7.1.2. Market Analysis and Forecast by Market Taxonomy 11.7.1.2.1. By Test Type 11.7.1.2.2. By Indication 11.7.1.2.3. By End User 11.7.2. Canada Market Analysis 11.7.2.1. Introduction 11.7.2.2. Market Analysis and Forecast by Market Taxonomy 11.7.2.2.1. By Test Type 11.7.2.2.2. By Indication 11.7.2.2.3. By End User 11.7.3. Mexico Market Analysis 11.7.3.1. Introduction 11.7.3.2. Market Analysis and Forecast by Market Taxonomy 11.7.3.2.1. By Test Type 11.7.3.2.2. By Indication 11.7.3.2.3. By End User 12. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Chile 12.3.1.3. Rest of Latin America 12.3.2. By Test Type 12.3.3. By Indication 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Test Type 12.4.3. By Indication 12.4.4. By End User 12.5. Market Trends 12.6. Drivers and Restraints - Impact Analysis 12.7. Country Level Analysis and Forecast 12.7.1. Brazil Market Analysis 12.7.1.1. Introduction 12.7.1.2. Market Analysis and Forecast by Market Taxonomy 12.7.1.2.1. By Test Type 12.7.1.2.2. By Indication 12.7.1.2.3. By End User 12.7.2. Chile Market Analysis 12.7.2.1. Introduction 12.7.2.2. Market Analysis and Forecast by Market Taxonomy 12.7.2.2.1. By Test Type 12.7.2.2.2. By Indication 12.7.2.2.3. By End User 13. East Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 13.3.1. By Country 13.3.1.1. China 13.3.1.2. Japan 13.3.1.3. South Korea 13.3.2. By Test Type 13.3.3. By Indication 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Test Type 13.4.3. By Indication 13.4.4. By End User 13.5. Market Trends 13.6. Drivers and Restraints - Impact Analysis 13.7. Country Level Analysis and Forecast 13.7.1. China Market Analysis 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Test Type 13.7.1.2.2. By Indication 13.7.1.2.3. By End User 13.7.2. Japan Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Test Type 13.7.2.2.2. By Indication 13.7.2.2.3. By End User 13.7.3. South Korea Market Analysis 13.7.3.1. Introduction 13.7.3.2. Market Analysis and Forecast by Market Taxonomy 13.7.3.2.1. By Test Type 13.7.3.2.2. By Indication 13.7.3.2.3. By End User 14. South Asia and Pacific Market Analysis 2018 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 14.3.1. By Country 14.3.1.1. India 14.3.1.2. ASEAN Countries 14.3.1.3. Australia and New Zealand 14.3.1.4. Rest of South Asia and Pacific 14.3.2. By Test Type 14.3.3. By Indication 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Test Type 14.4.3. By Indication 14.4.4. By End User 14.5. Market Trends 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis and Forecast 14.7.1. India Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Test Type 14.7.1.2.2. By Indication 14.7.1.2.3. By End User 14.7.2. ASEAN Countries Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Test Type 14.7.2.2.2. By Indication 14.7.2.2.3. By End User 14.7.3. Australia and New Zealand Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Test Type 14.7.3.2.2. By Indication 14.7.3.2.3. By End User 15. Western Europe Market 2018 to 2023and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. UK 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Nordic Countries 15.3.1.8. Rest of Western Europe 15.3.2. By Test Type 15.3.3. By Indication 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Test Type 15.4.3. By Indication 15.4.4. By End User 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis and Forecast 15.7.1. Germany Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Test Type 15.7.1.2.2. By Indication 15.7.1.2.3. By End User 15.7.2. France Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Test Type 15.7.2.2.2. By Indication 15.7.2.2.3. By End User 15.7.3. Spain Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Test Type 15.7.3.2.2. By Indication 15.7.3.2.3. By End User 15.7.4. Italy Market Analysis 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Test Type 15.7.4.2.2. By Indication 15.7.4.2.3. By End User 15.7.5. BENELUX Market Analysis 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Test Type 15.7.5.2.2. By Indication 15.7.5.2.3. By End User 15.7.6. Nordic Countries Market Analysis 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Test Type 15.7.6.2.2. By Indication 15.7.6.2.3. By End User 15.7.7. United Kingdom Market Analysis 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Test Type 15.7.7.2.2. By Indication 15.7.7.2.3. By End User 16. Eastern Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. Russia 16.3.1.2. Hungary 16.3.1.3. Poland 16.3.1.4. Rest of Eastern Europe 16.3.2. By Test Type 16.3.3. By Indication 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Test Type 16.4.3. By Indication 16.4.4. By End User 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis and Forecast 16.7.1. Russia Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Test Type 16.7.1.2.2. By Indication 16.7.1.2.3. By End User 16.7.2. Hungary Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Test Type 16.7.2.2.2. By Indication 16.7.2.2.3. By End User 16.7.3. Poland Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Test Type 16.7.3.2.2. By Indication 16.7.3.2.3. By End User 17. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 17.3.1. By Country 17.3.1.1. Saudi Arabia 17.3.1.2. Türkiye 17.3.1.3. South Africa 17.3.1.4. Other African Union 17.3.1.5. Rest of MEA 17.3.2. By Test Type 17.3.3. By Indication 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Test Type 17.4.3. By Indication 17.4.4. By End User 17.5. Market Trends 17.6. Drivers and Restraints - Impact Analysis 17.7. Country Level Analysis and Forecast 17.7.1. Saudi Arabia Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Test Type 17.7.1.2.2. By Indication 17.7.1.2.3. By End User 17.7.2. Türkiye Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Test Type 17.7.2.2.2. By Indication 17.7.2.2.3. By End User 17.7.3. South Africa Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Test Type 17.7.3.2.2. By Indication 17.7.3.2.3. By End User 17.7.4. Other African Union Market Analysis 17.7.4.1. Introduction 17.7.4.2. Market Analysis and Forecast by Market Taxonomy 17.7.4.2.1. By Test Type 17.7.4.2.2. By Indication 17.7.4.2.3. By End User 18. Market Structure Analysis 18.1. Market Share Analysis of Top Sponsors 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Branding and Promotional Strategies by Key Stakeholders 19.4. Key Competitive Deep Dive 19.4.1. Roche Diagnostics 19.4.1.1. Overview 19.4.1.2. Services Portfolio 19.4.1.3. Key Financials 19.4.1.4. SWOT Analysis 19.4.1.5. Key Developments 19.4.1.6. Sales Footprint 19.4.1.7. Strategy Overview 19.4.2. Siemens Healthineers 19.4.3. Bio-Rad Laboratories 19.4.4. Eagle Biosciences, Inc. 19.4.5. Biogenix Inc. Pvt. Ltd. 19.4.6. Diagnostic Automation/Cortez Diagnostics Inc. 19.4.7. BioSupply Ltd. 19.4.8. Bio-Diagnostics Ltd. 19.4.9. MERIDIAN BIOSCIENCE 19.4.10. Weldon Biotech, Inc. 19.4.11. Getein Biotech, Inc. 19.4.12. Creative Diagnostics 19.4.13. Beijing Strong Biotechnologies, Inc. 19.4.14. Merck KGaA 19.4.15. CTK Biotech, Inc. 19.4.16. Personal Diagnostics 19.4.17. Thermo Fisher Scientific Inc. 20. Assumptions and Acronyms Used 21. Research Methodology
Healthcare
January 2023
REP-GB-16356
300 pages
Explore Healthcare Insights
View Reports
Pulmonary Fibrosis Biomarker Market
